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1. Introduction
Immunostimulation based therapies hold promise of disease-specific interventions without
the toxicity and other side effects, which are associated with traditional therapeutic modalities.
Unfortunately, the exact manifestation of their therapeutic benefits and the mechanisms of
their action are still pending for most immunotherapeutic strategies. Virtually, such kinds of
treatments are ideal to establish standards of care and secure, as well as improve therapeutics
outcomes. A growing interest for studying and understanding immunostimulation based
therapeutics’ strategies has increased since, it could stimulate different components of innate
immunity and consequently stimulation of adaptive immunity [1-3].
These immunostimulation based therapies can be divided into two categories, nonspecific and
specific immunotherapies. Nonspecific immunotherapy describes therapies that are designed
to enhance the immune response without deliberately seeking to modulate the response to a
particular antigen. These therapies include three main categories. The first depends on
administration of certain agents that induces secretion of inflammatory cytokines that
nonspecifically activate the immune system [4]. The second depends on administration of
certain type of cytokine that can activate specific populations of immune cells. The third
category include the administration of antibodies that block immune checkpoints or other
suppressive pathways that are known to shut down the activity of immune system [5]. These
nonspecific activation pathways are crucial for the initiation of fully functional immune
responses encompassing both the innate and adaptive immune compartments [4].
© 2014 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
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Toll like receptors (TLRs) are a group of receptors that are expressed mainly in innate immune
cells, including macrophages, monocytes, dendritic cells, natural killer cells and mast cells [6].
These TLRs specifically recognize microbes as well as different microbial components called
TLR ligands. Interaction of TLR and TLR ligands trigger signaling pathways that lead to
activation of innate immune cells through secretion of a plethora of inflammatory mediators
including cytokines and chemokines [7, 8]. As such, different TLR ligands have been designed
to be used as adjuvant system,
The inclusion of TLR ligands as a potential new class of adjuvants candidates has enabled the
development of clinical effective vaccination strategies against many diseases [9, 10]. Polyi‐
nosinic-polycytidylic acid [Poly(I:C)] and its clinical grade poly-L-lysine (Poly-ICLC; Hilto‐
nol®) represent important members of these immunostimulatory vaccine adjuvants as has
been shown in several preclinical and clinical studies [11, 12]. In this review, we will introduce
a brief description of the TLR family followed by a description of the signaling pathway of
TLR and its role as a linker between innate and adaptive immunity. The structure, expression
and function of Poly(I:C) will be reviewed along with its potential application in cancer
vaccination, adoptive immunotherapy and chemo-immunotherapy in preclinical and clinical
trials.
2. Toll-like receptors (TLRs) and their agonists
TLRs are a class of transmembrane signaling proteins that play a critical role in initiation and
acceleration of innate and adaptive immune responses against different pathogen by recog‐
nizing these pathogens themselves or their products, including proteins, carbohydrates, lipids,
and nucleic acids (single-and double-stranded RNA and DNA) [13]. TLRs were discovered in
1985 by Christiane Nüsslein-Volhard as factors involved in the embryonic development and
resistance of the fly Drosophila to bacterial and fungal infection [14-16]. TLRs are pattern-
recognition receptors (PRR) with an extracellular leucine-rich repeats (LRRs) domain and a
conserved cytoplasmic domain homologous to that of the interleukin-1 receptor (IL-1R),
termed the Toll/IL-1R homology (TIR) domain [17, 18]. Such structure of TLRs recognizes
pathogen-associated microbial patterns (PAMPs) encoded in various pathogens. These
products include lipopolysaccharide (LPS), peptidoglycan (PGN), flagellin, bacterial DNA,
viral single and double stranded RNA and synthetic double-stranded RNA such as poly(I:C).
TLRs also recognize danger-associated molecular patterns (DAMPs) that are endogenous
molecules including intracellular proteins such as heat shock proteins (HSPs) and protein
fragments from the extracellular matrix (HMGB1) released from necrotic or dead cells [10,
19]. Given this capability of TLRs to recognize a wide range of microbial products and their
synthetic mimic, modulation of these receptors can significantly play a central role in shaping
the outcomes of the anti-microbial immunity. Since cancer originates from self-cells resulting
in a poor anti-tumor immunity if not tolerance, triggering TLR signaling pathways during
cancer immunotherapy by their specific agonists can accentuate the resultant anti-tumor
immunity.
TLRs expression profiles differ among tissues and cell types of the innate and adaptive immune
system. TLRs are predominantly expressed on T cells, B cells, neutrophils, monocytes, NK
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cells, mast cells, and antigen-presenting cells (APCs), such as macrophages (MΦ) or dendritic
cells (DCs). As such induction of TLR signaling activates APCs to provoke innate immunity
and to induce adaptive immunity [6, 7, 20]. More recently, TLR have been found to be expressed
on endothelial, epithelial cells and tumor cells, including melanoma [21]. TLRs are fundamen‐
tally located on the plasma membrane except TLR3, TLR7 and TLR9 that are located in the
endoplasmic reticulum (ER) [22-24]. Mammalian TLRs include a large family consisting of ten
to thirteen different types of TLRs that named simply TLR1 to TLR13 and each one of them
recognize specific microbial components [25].
To date, ten human and thirteen murine TLRs have been identified; TLR1 to TLR9 are
conserved between the human and mice. However, there are TLRs found in humans and not
present in all mammals. For example, TLR10 in humans is present in mice. On the other hand,
TLR11, TLR12 and TLR13 in mice are functional, but there is a stop codon in the human TLR11
TLR12 and TLR13 genes, which results in a lack of production of human TLR11 TLR12 and
TLR13 [26, 27]. Signaling pathways of these TLRs can be triggered by their specific ligands.
TLR ligands (TLRLs) are agents that bind to and activate TLRs. They are encoded in different
types of organisms at the cell surface or at the internal cell compartments and they are
expressed by different types of leucocytes and other cell types [28, 29].
TLRs/TLRLs bind results in a cascade of intra-cellular signaling pathways that induce the
production of inflammatory cytokines and immune response [7, 8]. TLRLs are recognized by
specific TLRs that are expressed on the surface of cells, for example, TLR2 is essential for the
recognition of bacterial lipoproteins, lipomannans and lipoteichoic acids [30], while TLR5
detects bacterial flagellin [31]. TLR4 has been reported to recognize bacterial cell wall compo‐
nent lipopolysaccharide (LPS) [30], and TLR11 which recognize a profilin-like protein of
Toxoplasma gondii [32] and uropathogenic E.coli [33]. In contrast, TLRs located within the
endoplasmic reticulum (ER) can detect microbial nucleic acids, for example, TLR3 is required
for response to virus-derived double-stranded RNA [34] and TLR9 recognize unmethylated
CpG motifs [35]. Whereas, TLR7 and TLR8 could recognize small synthetic antiviral molecules
[36], and single-stranded RNA [37].
3. TLRs Signaling pathways
Recent accumulating studies showed that TLRs signaling pathways can be divided into two
signaling pathways, the MyD88-dependent pathway which is common to all the TLRs that
resulted in the secretion of inflammatory cytokines, and TRIF-dependent pathway that is
specific for TLR3 and TLR4 which associated with the stimulation of IFN-β and the maturation
of dendritic cells [38-40].
3.1. MyD88-dependent pathway
The myeloid differentiation factor 88 (MyD88) dependent responses utilized by all TLRs except
TLR3 and its occurring on hetero-or homo-dimerization of the TLRs receptor, upon activation
by PAMPs or DAMPs. This dimerization induces the recruitment of adaptor proteins via the
Immunostimulatory Effects of Triggering TLR3 Signaling Pathway — Implication for Cancer Immunotherapy
http://dx.doi.org/10.5772/58575
153
cytoplasmic TIR domain. These adaptor proteins include the TIR-domain containing proteins,
TIRAP (TIR-associated protein), TRIF (TIR domain-containing adaptor protein-inducing IFN-
β) and TRAM (TRIF-related adaptor molecule), MyD88, Mal (MyD88 adaptor-like protein),
which triggers the TLR-mediated signaling pathways [41-45].
The transcription factor IRF7 is critical regulator for the production of IFN-α/β via MyD88
pathway. IRF7 presents in DCs is very low, and therefore TLR7, TLR8 and TLR9 operate mainly
through the NF-κB−IRF5 pathway [10, 46, 47]. It is worth noting that the transducing ability
of TLR7, TLR8 and TLR9 may change in favor of the IRF7 pathway. Whereas, TLR4 is located
on the cell membrane, activation of TLR4 signal transduction through MyD88/TIRAP and
TRAM/TRIF pathways leads to activation of innate immune responses, primarily through IRS
serine phosphorylationI
3.2. TRIF-dependent pathway
The TLR3 ligand (dsRNA) and the TLR4 ligand (LPS) activate the TRIF-dependent pathway
in which IRF-3 plays a key role. For TLR3 (dsRNA), activation of MyD88-independent
pathways occurs via TRIF (TIR domain-containing adaptor protein-inducing IFN-β). Upon
dsRNA binds within endosomes, TLR3 recruits the adaptor TRIF through a TIR–TIR interac‐
tion. TRIF, in turn, recruits RIP1 to activate NF-κB, via TRAFs and the IKK (IκB kinase)
complex. TRIF also recruits protein kinases TBK1/IKKε and TRAF3 to activate IRF3/7. Since,
IRF-3 can phosphorylate by TBK-1 and IKKε on C-terminal serines, leading to its dimerization
and translocation into the nucleus. Active IRF-3 mediates transcription of genes from the IFN-
β promoter. The secreted IFN-β binds to the IFN receptor (IFNR), and thus activates tran‐
scription of ISGs, such as IRF-7 [9, 48]. On the other hand, the intracellular dsRNA is recognized
by the RNA helicase RIG-I (or MDA-5). Activation of the latter activates TBK-1 and IKKε via
its CARD domain and activates IRF-3 as well. IRF-7 further stimulates transcription from the
IFN-α and-β promoters in a positive feedback loop. Type I IFNs bind also to their receptors to
trigger the JAK–STAT signaling pathway. Whereas, to induce inflammatory cytokines
production. TLR4 activation is requires both the MyD88-dependent and independent path‐
ways. This occurs via TIR domain containing adaptors TIRAP, MyD88, TRAM and TRIF, which
in turn initiates activation of NFκB, MAPK, and IRF3 allowing its nuclear localization and
production of IFN-β [40, 49].
The signaling pathway of TLRs is summarized in Figure 1. TLR7, TLR8 and TLR9 are present
in endosomes, which are stimulated by viral ssRNA. Upon activation, TLR7, TLR8 and TLR9
signal through the adaptor MyD88, which in turn leads to phosphorylation and activation of
IRF3. Following its activation, TLR3 signals through its adaptor TRIF, and thus activates non-
canonical IKK kinases (TBK1/IKKε), which subsequently phosphorylate both IRF3 and IRF7.
Active IRF-3 induces transcription from the IFN-β promoter. NF-κ β is also activated by TRIF
mediated signaling through canonical IKK kinases (IKKα, β, and γ). RIG-I and MDA5 are
located in cytoplasm and can recognize both ssRNA and dsRNA. Intracellular ssRNA and
dsRNA are recognized by the RNA helicase RIG-I (or mda-5), which are expressed in most
cells, activates TBK-1 and IKKε via its CARD domain through interaction with the mitochond‐
rially located adaptor MAVS.
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Different signal transducer and activator of transcription (STAT) family members can be
activated by interferons (IFNs). As a response to both type I IFNs and type II IFN (IFNγ)
stimulation, STAT1-STAT1 homodimers can be formed. These homodimers bind to IFNγ-
activated site (GAS) enhancer elements in the promoters of IFN-stimulated genes, and these
results in the induction of genes encoding pro-inflammatory cytokines and apoptotic factors.
STAT1 and STAT2 heterodimers, which are activated by binding with IRF9, which in turn
migrates to the nucleus to bind to IFN-stimulated response elements (ISREs) and activate
antiviral and antibacterial genes.
4. Polyinosinic-polycytidylic acid [Poly(I:C)]
Although, several previous studies have been extensively studied poly(I:C) for over 35 years
in humans [50, 51], it is receiving new interest as a crucial component in many new immu‐
nostimulatory combination therapeutic strategies. Poly(I:C) is a synthetic double-stranded
RNA (dsRNA) that has recently been identified as a specific ligand for TLR3 [52-55]. dsRNA
is a viral product produced by most viruses during their replication cycle, Both viral dsRNA
and its artificial mimic, poly(I:C), are potent inducers of type I interferons (IFN-α/β) [56, 57],
which is a crucial cytokines that exert anti-viral and immunostimulatory activities for both T
and B lymphocytes [58, 59], DCs [11, 60] and activate monocytes to produce CSF, IL-1β, IL-12,
and PGE2 [61, 62].
Several studies have been shown that Poly(I:C) induces a strong innate immune response
initiated by two types of PRRs; the TLRs and the RIG-I-like receptors (RLRs) which is a family
of cytoplasmic RNA helicases that includes RIG-I and MDA-5 [63-67]. In addition, several
studies have shown that Poly(I:C) transduces signals which activate the NF-κB and the IFN-
β promoter [53, 54] and activates several nuclear and cytoplasmic enzyme systems such as
oligoadenylate synthetase (OAS), the dsRNA dependent protein kinase R (PKR), RIG-I
Helicase, and MDA5 (melanoma differentiation associated gene) which are implicated in
antiviral and antitumor host defenses [7].
Poly(I:C) interact with TLR3, that is the specific intracellular recognition system that responds
and signals to the intracellular presence of dsRNA and RNA virus infection [68]. TLR3 is
mainly expressed on a broad range of antigen-processing cells (APCs), dendritic cell (DC)
subsets, fibroblasts, intestinal epithelial [54, 69, 70] monocytes, macrophage (MΦ), mast cells,
NK cells [71, 72], CD4+and CD8+T cells [6, 73]. Several prior studies have shown that poly(I:C)
has potent pleiotropic immunostimulatory effects on several kinds of immune cells [74-76].
Poly(I:C), a synthetic dsRNA mimic copolymer, is a specific TLR3 agonist [13, 77]. Recently,
we and others have reported that in vivo administration of the TLR3 agonist poly(I:C) into
naïve mice induced rapid increases in the frequencies of NK cells mainly in the liver and that
these effects associate with better antigen specific responses and antitumor efficacy [6, 78-81].
Consistent with earlier studies [81], we have demonstrated that the adjuvant effects of poly(I:C)
to the antigen-specific CD8+T cell responses are partially dependent on NK cells through
creation of a rapid beneficial cytokine milieu [82, 83]. Furthermore, in vitro treatment of highly
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purified NK cells with poly(I:C) significantly augmented NK cell-mediated cytotoxicity and
up-regulated their expression of the activation marker CD69 [71]. Of particular interest, similar
to viral infection, poly(I:C) treatment has been found to preferentially induce recruitment and
activation of hepatic NK cells [79] and their trafficking to spleen coincided with enhanced
cytokine expression [80]. These studies may explain the increased antitumor effects against
metastasis observed in tumor models after poly(I:C) treatment [84].
5. Poly(I:C) and anti-tumor Immunity
A fundamental difference between tumor and microbes is that only the latter encode products
(signatures) that are recognized as “danger signals” by pathogen recognition receptors (PPRs)
expressed in the innate immune cells. [85] In most cases, immune system can mount vigorous
immune responses against microbes, but not against cancer. Therefore, the challenge in cancer
immunotherapy is how to manipulate the body's own immune system to fight cancer. [86]
Mimicking the anti-microbial immunity, recent preclinical and clinical studies have establish‐
ed that provision of TLRL adjuvant system systemically or into tumor environment itself
profoundly awaken the cross talk between innate and adaptive immunity, driving generation
of efficacious anti-tumor immunity. [87] For instance, the addition of CpG DNA (typical
TLR9L) to a melanoma vaccine resulted in effective cytolytic responses. [88] Imiquimod, a
synthetic TLR7/8L, has been successfully used in the treatment of basal cell carcinoma [89,
90] and to enhance the immunogenicity of vaccine containing Flt3 ligand and a melanoma
peptide. [91] MPL, a TLR4L, has been used as an adjuvant in clinical trials of vaccines against
melanoma, glioma and pancreatic and colorectal carcinoma, inducing substantial tumor-
specific immunity in response to vaccination [92, 93]. We have reported recently that co-
administration of the TLR3L poly(I:C) in vivo with peptide vaccination established functional
effector/memory responses [94] by induction of NK-driven beneficial cytokine milieu and DC
activation. [81] Although the impact of both of TLRLs at the time of Ag priming has been the
focus of several studies, their impacts at the time of Ag recall on the tumor-specific memory
responses have not been actively investigated.
Since, cancer cells do not encode danger signals like virus, generation of anti-tumor memory
T cells in the tumor setting would require a large pool of highly activated DCs. In response to
TLRLs, resident immature DCs at the site of vaccination undergo a maturation program and
migrate to the draining lymph nodes (LNs) [72, 95, 96]. Therefore, utilizing TLRLs is a potential
approach to induce activation of immature DCs and maximize their contribution to memory
cell responses. In line with this notion, recent studies have established the adjuvant effects of
several TLRLs, in particular, TLR3L (poly(I:C), TLR7/8L (Imiquimod), and TLR9L (CpG) to the
anti-tumor CD8+T cell responses [81, 94, 97-101]. However, most of these studies tested the
adjuvant effects of TLRLs in lymphodepleted hosts, and those few studies that utilized
lymphodepleted hosts did not use adoptive cell therapy (ACT) system [98, 102-107].
Because the frequency of DCs in steady state condition is low, growth factors in particular
Flt3L and G-CSF have been used to mobilize DCs in vivo [108-110]. With this regard, we have
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recently reported a rapid induction of type I IFNs and activation of DCs with decreases in the
levels of Treg cells after CTX treatment; resulting in augmented post vaccination responses
which were further improved by addition of poly(I:C) to vaccination [111]. We have found
also a marked expansion of immature DCs during the recovery phase after treatment with the
anticancer drug cyclophosphamide (CTX), indicating to the mobilizing effect of CTX for DCs.
Since DCs are equipped with TLRs that sense different microbial products such as poly(I:C),
activation of these immature DCs in vivo may augment memory T cell responses. [85]. Recent
studies, including ours have demonstrated the adjuvant effects of TLRLs to ACT in lympho‐
depleted hosts [112-114]. These studies suggest that combinatorial treatments with chemo‐
therapy/immunotherapy and ACT can markedly improve memory T cell responses. Our
observation of expansion of DCs post CTX therapy is a suitable model to dissect the optimal
timing of the adjuvant effects of TLRLs to post vaccination responses of ACT in a lymphode‐
pleted host.
Specifically, our recent studies showed that treatment of a recipient host with the non mye‐
loablative dose of CTX augments post vaccination CD8+T cell responses, which were associated
with a quick activation of DCs in the lymphopenic phase [114]. We also found that CTX induces
increases in the numbers of immature DCs during the recovery phase from days 9-16, peaking
on day 12 [115]. These DCs demonstrated normal phagocytic ability in vitro and antigen uptake
in vivo. Administration of poly(I:C) at the peak of DC expansion resulted in induction of rapid
inflammatory milieu which associated with significant increases in the numbers of activated
(CCR7highCD40high) DCs in lymph nodes.
Using the pmel-1 TCR transgenic mouse model, in which CD8+T cells can recognize the natural
tumor gp100 antigen on B16 melanoma, we demonstrated that vaccination of CTX-lympho‐
depleted mice with the MHC class-I melanoma gp100 peptide and poly(I:C) during the
lymphopenic phase (day 2) and at the peak of DC expansion (day 12) resulted in significant
augmentation in the number of activated DCs in lymph nodes with a temporal increase in the
expansion of pmel-1 cells. Conditional depletion studies of DCs at day 12 before revaccination
of CTX-treated recipient mice revealed that DCs are required for the optimal pmel-1 cell
responses. Importantly, the therapeutic anti-tumor effects of the enhanced pmel-1 cell
responses were demonstrated toward an advanced tumor of the poorly immunogenic B16
melanoma, indicating the clinical significance of our observation. Furthermore, we have found
improvement in DCs expansion when CTX treatment was followed by a daily treatment with
5µg/mouse G-CSF for 5 days [6], without altering the efficacy of our prime-boost vaccination
with hgp100/poly(I:C) [116].
Treg cells express different TLRs [117] and can be activated by certain TLR agonists such as
TLR4 [118-120], and TLR5 [121], and can be inactivated by TLR2 and TLR7/8 agonists [122,
123]. Indeed, total body irradiation and CTX-preconditioned hosts demonstrated that inter‐
ference with Treg cell activities can enhance tumor-specific T cell responses and anti-tumor
immunity [124], [125, 126]. Our preliminary studies and previous studies [105, 125-130],
however, showed that although Treg cells decrease in numbers during the lymphopenic phase
after CTX treatment they recover to their normal levels at the recovery phase. These recovered
Treg cells may interfere with the efficacy of vaccination at recovery phase unless the vaccination
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is co-administered with a potent adjuvant that can block Treg cell function. Indeed, induction
of maturation of DCs by certain TLR agonists has been found to control Treg cell function in
vivo [122, 131, 132]. Therefore, it is possible that the enhanced pmel-1 cell expansion and anti-
tumor effects of pmel-1 cells to peptide/poly(I:C) revaccination on day 12 post CTX treatment
involve blocking of Treg cell.
The potent anti-tumor efficacy of prime-boost vaccination with tumor antigen/poly(I:C) at
precise time points post CTX therapy would lead to its potential application in the clinical
setting. We would envision two treatment protocols for the clinical application of this prime-
boost vaccination with tumor peptide and poly(I:C) on cancer (e.g. melanoma) patients. 1)
Patients  can  be  with  a  lymphodepletion  dose  of  CTX  followed  by  G-CSF  to  correct
leucopenia, and vaccinate the patient with a candidate tumor Ag (gp100, MART, or TRP2)
with co-administration of the clinical grade form of poly(I:C) such as Hiltonol®. Vaccina‐
tion and Hiltonol® treatments can be repeated during the recovery from leucopenia (after
10-15 days of chemotherapy) when the numbers of DCs are increased. 2) The same as above
but with adoptive transfer of peripheral blood mononuclear cells harvested from the cancer
patient prior chemotherapy. These cells can be stimulated in vitro with 1ng/mL of the tumor
antigens in the presence of  10ng/mL IL-12 for 3-5 days as we recently described in our
preclinical model [133].
6. Poly(I:C) and antiviral immune response
The innate immune response is the first barrier against the invading pathogens and viruses
and it responds through activating inflammatory and antiviral defense mechanisms by
inducing IFNs-α/β against the viruses [134]. Several in vitro and in vivo studies have demon‐
strated that the main effects of poly(I:C) is the induction of IFNs-α/β, which play a crucial role
in innate anti-viral response [135, 136].Several studies have been extensively demonstrated
that poly(I:C) triggers the activation of PKR and other kinases which followed by the phos‐
phorylation of the substrates of these enzymes that results in the subsequent translocation of
transcription factors, NF-ҚB and IRF-3, to the nucleus where then they bind to the IFN-β
promoter to form a transcription complex that induce IFN-β production [137-140]. It has been
thought that the proximal inducer of IFNs-α/β is intracellular dsRNA generated as an
intermediate during viral replication [53].
Recently, it has been shown that dsRNA and ssRNA molecules are recognized as intermediate
by TLRs that is expressed on DCs, NK cells, MΦ and epithelium during virus replication [141].
Several studies have been extensively demonstrated that Poly(I:C) plays a critical role in
inducing innate immune response against many viruses, such as influenza virus [142], human
respiratory syncytial virus (RSV) [143], herpes simplex virus 2 (HSV-2) [144], and murine
cytomegalovirus [25]. Several in vitro and in vivo studies have been shown that retinoic-acid-
inducible gene I (RIG-I) and melanoma-differentiation-associated gene 5 (MDA-5), are the key
in the detection of viral dsRNA and Poly(I:C) in the cytosol and subsequent eradication of the
replicating viral genomes [66, 145, 146]. Treatment of animals with poly(I:C) results inactiva‐
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tion of the TLR3 receptor which in turn induces the activation of NF-κB and the production of
type I interferons that induces strong antiviral and antineoplastic effects accompanied by
activation of CD8+T and NK cells [53, 147]. In addition, poly(I:C) is shown to serve as an
adjuvant to induce protective CD4+T cell responses against HIV [148].
7. Poly(I:C) and clinical trials
7.1. Hiltonol®
Hiltonol® or Poly-ICLC is a synthetic, nuclease-resistant, hydrophilic complex of polyino‐
sinic and polycytidylic acid, stabilized with poly-L-lysine and carboxymethyl cellulose. Poly-
ICLC  is  IFN-β  inducer,  which  is  known  to  steady  the  blood-brain-barrier  (BBB)  and
minimize cellular infiltration into damaged brain regions following stroke [149, 150]. Several
clinical trials were conducted to utilize poly-ICLC as an IFN inducer in cancer patients, the
first clinical trial (phase 1) were conducted to determine the maximum tolerated dose (MTD)
and it  found that the MTD was (12 mg/m2),  which induced effective response in cancer
patients [51]. Another study was conducted to determine the immunomodulatory effect of
Poly-ICLC in cancer  patients  and it  showed that  there  was no detectable  serum IFN in
patients  that  received  1  mg/m2  Poly-ICLC  by  IM  injection  [151].  In  contrast,  IFN  was
detectable in the serum of patients that received 4 mg/m2 Poly-ICLC by IV injection. Then,
phase I and II clinical trials were conducted in patients with many types of cancers including
leukemia, lymphoma, brain tumors, myeloma, juvenile laryngeal papillomatosis, renal cell
carcinoma, breast cancer, ovarian cancer, and melanoma [152-160].
In most of these early clinical trials, about 6 mg/m2 Poly-ICLC was generally used intrave‐
nously. Fever, often with temperatures greater than 40°C, was a universal adverse event in the
trials and was the primary dose-limiting factor. Other common adverse events reported in
these trials included nausea, vomiting, hypotension, thrombocytopenia, leukopenia, arthral‐
gia, myalgia, and fatigue. Additionally, very few objective responses were reported in these
clinical trials. Due to its toxicity and relative ineffectiveness, utilizing Poly-ICLC was deserted
after the availability of recombinant IFN. It was subsequently determined that lower doses (10
to 50 mg/kg) of Poly-ICLC resulted in a broader host defense stimulation, a potent adjuvant
effect, and a specific antiretroviral effect mediated by the 2’5’OAS and PKR nuclear enzyme
systems [161]. Consequently, Poly-ICLC is currently being developed for use only at doses up
to 50 mg/kg. The poly-ICLC treatment prior to exposure to oxygen-glucose deprivation
maintained the paracellular and transcellular transport across the endothelium and attenuated
the drop in transendothelial electric resistance by enhancing IFN-β mRNA expression in
astrocytes and microglia [162]. Recent study utilized poly-ICLC in activation of TLR3 signal‐
ing, which exerts a beneficial effect on NK cells, resulting in the increased cetuximab-depend‐
ent lysis of head and neck cancer (HNC) cells [163].
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7.2. Ampligen®
Ampligen®  is  known  as  [poly(I)-poly(C12U)]  that  is  composed  of  poly(IC)  with  a  U
mismatch at every 12th base of the C strand. The main effect of Ampligen® is the induction
of Th1 response. This has been demonstrated in delayed-type hypersensitivity reactions and
in current clinical studies with human immunodeficiency virus-infected patients. Other cells
targeted are NK cells, cytotoxic CD8+T cells, and LAK-NK cells. Despite initial trials in the
1990s, little is known about Ampligen®, since; it is not routinely used in clinical practice.
However,  due to its  notable and potent antiviral  effects,  Ampligen® has been generally
well tolerated in randomized clinical trials [164, 165]. Since, Ampligen® did not consistent‐
ly  produce  antiviral  effects,  but  its  antiviral  activity  was  always  seen  after  therapeutic
treatment.  Therefore,  it  was assumed that  Ampligen have exquisite  specificity  for  TLR3
[166, 167]. Early studies showed that treatment of chronically HBV-infected chimpanzees
with polyICLC transiently reduced the levels of serum viral DNA, HBsAg and HBeAg [168].
In two independent studies, transient suppression of DHBV in ducks by Ampligen® was
also observed [169, 170]. In vitro studies, Ampligen and zidovudine have combined: to act
in  synergy  against  HIV-1-infected  cell  lines  [171,  172]  and  enabling  restoration  of  the
immune  function  in  HIV-infected  individuals.  Wither  through  maintaining  a  stable  or
raising CD4 count, increasing delayed-type hypersensitivity reaction, and reducing rate of
progression to AIDS [173].
More recently, Nicodemus et al (2010) evaluated polyIC12U and confirmed the potential of
TLR3 stimulation with Ampligen® in enhancement bioactivity of cancer immunotherapies
[166]. Their results revealed that Ampligen® is a potent inducer for the dendritic cell matura‐
tion and local cytokines producing in culture systems including IL-4, IL-6, IL-12p70, IFN g,
MIP-1a and TNF α. Interestingly, treatment of wild-type mice with Ampligen® 24 hours
following infection with a lethal viral inoculation was fully protective, whereas dosing 4 h
prior to inoculation is ineffective in preventing mortality [167]. Intranasal Ampligen®
administered to mice in conjunction with prototype avian flu vaccines, greatly enhances the
cellular and humoral immunity achievable with the vaccine and also protects mice from lethal
infection [174].
8. Conclusion
Since the discovery of the important role of TLRs in innate immunity and the initiation of an
immune response that follows the activation of antigen-specific acquired immunity, rapid
progress has been made on our understanding of the molecular mechanisms of TLRs. The
inclusion of TLR ligands as a potential new class of adjuvants candidates has enabled the
development of clinical effective vaccination strategies against many diseases. Poly(I:C) and
Poly-ICLC represent two important member of these immunostimulatory vaccine adjuvants
in mice, nonhuman primates and in human. TLR3 is specifically expressed in quite cell-type
and species; it is expressed in specific myeloid cells, vascular endothelial cells and airway
epithelial cells among others. Human TLR3 is highly expressed in immature DCs whereas
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mouse TLR3 is highly expressed in macrophages, but in both species, its expression is induced
by IFN.
Unlike other TLRs, TLR3 is unique, since, it is not required MyD88 for signaling, and instead,
TRIF is the critical adaptor protein for its signaling. Whereas TLR3 displays a distinct intra‐
cellular localization compared with other TLRs, TLR7 and TLR9 trigger a quick, but short IFN
response, whereas TLR3 might be more important for a prolonged response and the initiation
of the adaptive immune response. Poly(I:C) interact with TLR3 that responds and signals to
the intracellular presence of dsRNA and RNA virus infection. Poly(I:C), is strong inducers of
IFN-α/β, which is a crucial cytokines that exert anti-viral and immunostimulatory activities
for both T and B lymphocytes, DCs and activate monocytes to produce CSF, IL-1β, IL-12, and
PGE2. It’s also transduces signals which activate the NF-κB and the IFN-β promoter and
activates several nuclear and cytoplasmic enzyme systems such as OAS, PKR, RIG-I Helicase,
and MDA5 which are implicated in antiviral and antitumor host defenses.
The above mentioned pleotropic effects of the TLR3 agonist Poly(I:C) makes it as a candidate
adjuvant system for anti-viral and anti-tumor immune responses, in particular its clinical forms
Hiltonol® and Ampligen® induce similar immunomodulatory effects with accepted side
effects.
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